Systematic Financial Management LP reduced its position in shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) by 48.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 86,280 shares of the company’s stock after selling 80,240 shares during the period. Systematic Financial Management LP’s holdings in Endo International were worth $1,452,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. United Services Automobile Association lifted its holdings in shares of Endo International by 16.7% during the 2nd quarter. United Services Automobile Association now owns 41,508 shares of the company’s stock worth $391,000 after acquiring an additional 5,933 shares during the period. Xact Kapitalforvaltning AB lifted its holdings in shares of Endo International by 22.2% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 35,715 shares of the company’s stock worth $337,000 after acquiring an additional 6,500 shares during the period. James Investment Research Inc. lifted its holdings in shares of Endo International by 594.9% during the 3rd quarter. James Investment Research Inc. now owns 10,945 shares of the company’s stock worth $184,000 after acquiring an additional 9,370 shares during the period. Diamond Hill Capital Management Inc. lifted its holdings in shares of Endo International by 1.0% during the 2nd quarter. Diamond Hill Capital Management Inc. now owns 1,100,259 shares of the company’s stock worth $10,375,000 after acquiring an additional 10,600 shares during the period. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Endo International during the 3rd quarter worth about $223,000.

Several brokerages have recently weighed in on ENDP. Cantor Fitzgerald set a $12.00 price objective on shares of Endo International and gave the stock a “hold” rating in a report on Wednesday, August 8th. Canaccord Genuity set a $13.00 price objective on shares of Endo International and gave the stock a “hold” rating in a report on Wednesday, August 1st. ValuEngine upgraded shares of Endo International from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 25th. BMO Capital Markets increased their price objective on shares of Endo International from $9.00 to $16.00 and gave the stock a “market perform” rating in a report on Friday, August 10th. They noted that the move was a valuation call. Finally, Royal Bank of Canada upgraded shares of Endo International from a “sector perform” rating to an “outperform” rating and set a $26.00 price objective on the stock in a report on Monday, August 13th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $15.44.

In related news, Director Nancy J. Hutson sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $12.83, for a total value of $128,300.00. Following the transaction, the director now owns 49,970 shares in the company, valued at $641,115.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.80% of the company’s stock.

NASDAQ ENDP opened at $12.69 on Monday. Endo International PLC has a one year low of $5.27 and a one year high of $18.50. The company has a market capitalization of $2.85 billion, a P/E ratio of 3.30, a price-to-earnings-growth ratio of 4.64 and a beta of 0.65.

Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings results on Thursday, November 8th. The company reported $0.71 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.12. Endo International had a negative net margin of 37.82% and a positive return on equity of 1,348.52%. The firm had revenue of $745.00 million for the quarter, compared to analyst estimates of $694.93 million. During the same quarter last year, the firm posted $0.91 earnings per share. Endo International’s revenue for the quarter was down 5.3% compared to the same quarter last year. As a group, equities analysts expect that Endo International PLC will post 2.73 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Systematic Financial Management LP Has $1.45 Million Holdings in Endo International PLC (ENDP)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/11/19/systematic-financial-management-lp-has-1-45-million-holdings-in-endo-international-plc-endp.html.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Further Reading: Tariff

Want to see what other hedge funds are holding ENDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endo International PLC (NASDAQ:ENDP) (TSE:ENL).

Institutional Ownership by Quarter for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.